Hannah Wei Wu1, Zhi-Qiang Fu2, Ke Lu2, Sunthorn Pond-Tor3, Rui Meng4, Yang Hong2, Kai Chu4, Hao Li2, Mario Jiz5, Jin-Ming Liu2, Ming Hou4, Sangshin Park3, Jiao-Jiao Lin2, Jonathan D Kurtis6. 1. Center for International Health Research, Rhode Island Hospital, Brown University Medical School, Providence, RI 02903, USA. Electronic address: Haiwei_Wu@Brown.edu. 2. Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, 518 Ziyue Road, Minhang, Shanghai 200241, China. 3. Center for International Health Research, Rhode Island Hospital, Brown University Medical School, Providence, RI 02903, USA. 4. Department of Pathogen Biology, Nanjing Medical University, 140 Hanzhong Road, Nanjing 210029, China. 5. Department of Immunology, Research Institute of Tropical Medicine, Manila, Philippines. 6. Center for International Health Research, Rhode Island Hospital, Brown University Medical School, Providence, RI 02903, USA. Electronic address: Jonathan_Kurtis@Brown.edu.
Abstract
BACKGROUND: Schistosomiasis japonica is a zoonosis and presents significant public health problems in China and the Philippines. Vaccines targeting domestic animals constitute attractive control measures. METHODS: We conducted three vaccine trials to evaluate the protective efficacy of recombinant full-length paramyosin (rSj97) in water buffalo. Animals were immunized with 3 doses of rSj97 adjuvanted with ISA206 at 250μg/dose or 500μg/dose at 4wk intervals before challenge with 1000 Schistosoma japonicum cercariae. The primary outcome was worm burden assessed by portal perfusion 8-10weeks post challenge. Safety measures included weight, temperature, body condition score, hemogram and routine assays for hepatic and renal function. RESULTS: The three-dose regimen was well tolerated in all three trials. In the first trial, vaccinated buffalo had 51.5% lower worm burden post challenge compared to controls. In the second trial, buffalo immunized with 500μg/dose of rSj97 had 57.8% lower worm burden compared to controls (p=0.026). A similar but not significant reduction (60.9%) was observed with animals administered with 250ug rSj97/dose. In the third trial, buffalo immunized with a 500μg/dose of rSj97 had 57.8% lower worm burden compared to controls (p=0.014). CONCLUSIONS: These findings indicated that rSj97 is a safe and promising vaccine candidate for schistosomiasis japonica in water buffalo.
BACKGROUND:Schistosomiasis japonica is a zoonosis and presents significant public health problems in China and the Philippines. Vaccines targeting domestic animals constitute attractive control measures. METHODS: We conducted three vaccine trials to evaluate the protective efficacy of recombinant full-length paramyosin (rSj97) in water buffalo. Animals were immunized with 3 doses of rSj97 adjuvanted with ISA206 at 250μg/dose or 500μg/dose at 4wk intervals before challenge with 1000 Schistosoma japonicum cercariae. The primary outcome was worm burden assessed by portal perfusion 8-10weeks post challenge. Safety measures included weight, temperature, body condition score, hemogram and routine assays for hepatic and renal function. RESULTS: The three-dose regimen was well tolerated in all three trials. In the first trial, vaccinated buffalo had 51.5% lower worm burden post challenge compared to controls. In the second trial, buffalo immunized with 500μg/dose of rSj97 had 57.8% lower worm burden compared to controls (p=0.026). A similar but not significant reduction (60.9%) was observed with animals administered with 250ug rSj97/dose. In the third trial, buffalo immunized with a 500μg/dose of rSj97 had 57.8% lower worm burden compared to controls (p=0.014). CONCLUSIONS: These findings indicated that rSj97 is a safe and promising vaccine candidate for schistosomiasis japonica in water buffalo.
Authors: Bayani L Blas; Manuel I Rosales; Ignacio L Lipayon; Kazuo Yasuraoka; Hajime Matsuda; Masataka Hayashi Journal: Parasitol Int Date: 2004-06 Impact factor: 2.230
Authors: D P McManus; J Y Wong; J Zhou; C Cai; Q Zeng; D Smyth; Y Li; B H Kalinna; M J Duke; X Yi Journal: Vaccine Date: 2001-12-12 Impact factor: 3.641
Authors: M G Taylor; M C Huggins; F Shi; J Lin; E Tian; P Ye; W Shen; C G Qian; B F Lin; Q D Bickle Journal: Vaccine Date: 1998-08 Impact factor: 3.641
Authors: Adebayo J Molehin; Sean A Gray; Cheri Turner; Jennifer Davis; Weidong Zhang; Sabiha Khatoon; Madison Rattan; Rebecca Kernen; Christopher Peterson; Souad R Sennoune; Darrick Carter; Afzal A Siddiqui Journal: Front Immunol Date: 2021-02-23 Impact factor: 7.561